GlassScriptPhysician profile
Anthony A Starpoli
NPI 1477633642
$53,040.80
in general payments reported to CMS, 2019-2025
25 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $585 · 2021: $674 · 2022: $432 · 2023: $371 · 2024: $25K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $14K · Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,750.00 |
| Travel and Lodging | $13,905.88 |
| Food and Beverage | $3,319.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46,829.16 | 2024-2025 | Voquezna |
| Capsovision, INC. | $1,400.00 | 2019 | |
| Qol Medical, LLC | $878.55 | 2019-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $641.76 | 2019-2025 | Wegovy, Saxenda |
| Endogastric Solutions, INC | $609.94 | 2019-2020 | |
| Olympus America INC. | $438.73 | 2019-2025 | Single Use Repositionable Clip, Visiglide |
| Micro-Tech Endoscopy USA, INC. | $381.72 | 2019-2025 | Lesionhunter |
| Boston Scientific Corporation | $287.33 | 2024-2025 | Wallflex Duodenal, Overstitch Nxt Endoscopic Suturing System |
| Covidien LP | $232.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.37 | 2021-2024 | Entyvio |
| Lilly USA, LLC | $151.36 | 2022-2025 | Zepbound |
| Medtronic, INC. | $147.10 | 2021 | |
| Steris Corporation | $144.41 | 2025 | |
| Redhill Biopharma INC. | $135.66 | 2020-2023 | Talicia |
| Madrigal Pharmaceuticals | $123.92 | 2025 | Rezdiffra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.48 | 2021 | |
| Abbvie INC. | $85.94 | 2020-2025 | |
| 3-D Matrix, INC. | $65.57 | 2024 | |
| Celgene Corporation | $61.68 | 2022-2023 | Zeposia |
| Lucid Diagnostics INC. | $52.97 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.05 | 2020 | |
| Ambu INC. | $21.11 | 2024 | |
| Celltrion USA INC. | $19.74 | 2024 | Vegzelma |
| Merz North America, INC. | $18.76 | 2019 | |
| Daiichi Sankyo INC. | $16.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Starpoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.